Evidence map›Paper›PMID 27757792›Full record

ReviewWorld journal of microbiology & biotechnology2016

Synthesis and purification of galacto-oligosaccharides: state of the art.

Carlos Vera, Andrés Córdova, Carla Aburto, Cecilia Guerrero, Sebastián Suárez, Andrés Illanes

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of microbiology & biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
11.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 147 citations in OpenAlex.

  1. Review
  2. Galactooligosaccharide Production Using ImmobilizedInternational journal of molecular sciences · 2025
    Article
  3. Characterization of a β-Galactosidase fromMolecules (Basel, Switzerland) · 2025
    Article
  4. Review
  5. A NewFoods (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Overview of the Importance of Biotics in Gut Barrier Integrity.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Carlos VeraSchool of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Av. Brasil, 2085, Valparaíso, Chile.
Andrés CórdovaSchool of Food Engineering, Pontificia Universidad Católica de Valparaíso, Waddington 716, Playa Ancha, Valparaíso, Chile. andres.cordova@pucv.cl.
Carla AburtoSchool of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Av. Brasil, 2085, Valparaíso, Chile.
Cecilia GuerreroSchool of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Av. Brasil, 2085, Valparaíso, Chile.
Sebastián SuárezSchool of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Av. Brasil, 2085, Valparaíso, Chile.
Andrés IllanesSchool of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Av. Brasil, 2085, Valparaíso, Chile.
Pontificia Universidad Católica de Valparaíso · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactose-derived non-digestible oligosaccharides are prominent components of functional foods. Among them, galacto-oligosaccharides (GOS) outstand for being prebiotics whose health-promoting effects are supported on strong scientific evidences, having unique properties as substitutes of human milk oligosaccharides in formulas for newborns and infants. GOS are currently produced enzymatically in a kinetically-controlled reaction of lactose transgalactosylation catalyzed by β-galactosidases from different microbial strains. The enzymatic synthesis of GOS, although being an established technology, still offers many technological challenges and opportunities for further development that has to be considered within the framework of functional foods which is the most rapidly expanding market within the food sector. This paper presents the current technological status of GOS production, its main achievements and challenges. Most of the problems yet to be solved refer to the rather low GOS yields attainable that rarely exceed 40 %, corresponding to lactose conversions around 60 %. This means that the product or reaction (raw GOS) contains significant amounts of residual lactose and monosaccharides (glucose and galactose). Efforts to increase such yields have been for the most part unsuccessful, even though improvements by genetic and protein engineering strategies are to be expected in the near future. Low yields impose a burden on downstream processing to obtain a GOS product of the required purity. Different strategies for raw GOS purification are reviewed and their technological significance is appraised.

Indexed as

beta-GalactosidaseBioreactorsFermentationFood IndustryIndustrial MicrobiologyLactoseMonosaccharidesOligosaccharidesbeta-GalactosidaseLactoseMonosaccharidesOligosaccharidesDownstreamEnzymatic synthesisGalacto-oligosaccharidesLactosePrebiotic

Identifiers

PMID27757792
OpenAlexW2536751971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.